Mach7 Technologies (ASX: M7T) has signed a five-year annual subscription licence contract with American Radiologist Network Inc. (AMRADNET), a US teleradiology provider.
The deal is for Mach7's advanced eUnity Viewer product, with an initial contract value of A$1.7M, based on a minimum of 0.675M studies per annum.
This provides a clear, recurring revenue stream for Mach7.
A standout feature of this new contract is the significantly accelerated deployment timeline.
Commercial Transformation Underway
First productive use is expected within 45 days from the contract effective date, a substantial reduction compared to Mach7's typical 12-month deployment timeframe.
Mach7 attributes this rapid deployment to its ongoing sales and services restructuring, which includes the removal of organisational silos.
This reflects the effectiveness of the company's commercial transformation strategy.
The projected volumes for the AMRADNET contract are expected to exceed 1M studies during the 5-year term, showcasing the scalability of the eUnity Viewer in high-volume teleradiology environments.
Operational Reset and Flamingo Architecture
This contract win aligns with Mach7's broader strategy, as highlighted in its Q3 FY26 results.
The company has been executing an operational reset, demonstrating improving delivery execution and cost discipline.
A key focus for Mach7 is its modular 'Flamingo Architecture', designed to expand revenue pathways and is expected to contribute to annual recurring revenue (ARR) growth in the second half of FY26 and into FY27.
While FY26 revenue was projected to be approximately 15% below FY25, Mach7 has maintained a focus on strengthening its ARR run rate and expanding its partner ecosystem, with 10 active partners across four categories.
Recent Performance and Capital Management
Half-year FY26 results indicated that total revenue declined due to fewer one-off capital licence deals and customer churn, which impacted profitability metrics such as adjusted EBITDA.
Despite this, Mach7 maintained a strong financial position, reporting closing cash of A$19.2M at 31 December 2025 and no debt.
This provides a robust foundation for ongoing strategic execution.
In March 2026, Mach7 completed its on-market share buy-back program. The company purchased 6,273,000 shares for a total consideration of $2.24M at an average price of $0.3501 per share.
Amradnet Deal Signals Execution Improvement
The new AMRADNET contract demonstrates Mach7's ability to accelerate deployment cycles, a key indicator of its commercial transformation efforts.
While past performance showed revenue headwinds, this win, coupled with progress on its Flamingo Architecture, suggests a more efficient path to revenue realisation and market penetration.
